Year All2024202320222021202020192018201720162015201420132012201120102007 07.27.16 Syndax Appoints Leading Experts to Scientific Advisory Board (SAB) WALTHAM, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on the development of novel anti-cancer therapies, announced the appointment of seven leading oncology experts to its Scientific Advisory Board (SAB). Read More 07.20.16 Syndax to Announce Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 9, 2016 WALTHAM, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its second quarter 2016 financial results on Tuesday, August 9, 2016, before the opening of the U.S. financial markets. In connection with the earnings release, Syndax's management will host Read More 07.07.16 Syndax Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference WALTHAM, Mass., July 07, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy across multiple cancer indications, today announced that Chief Executive Officer, Briggs Morrison, M.D., Read More 07.06.16 Syndax Expands Pipeline With Exclusive Worldwide License Agreement for UCB's Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program IND-ready immuno-oncology agent has best in class potential Read More 06.14.16 Syndax Pharmaceuticals to Present at the JMP Securities Life Sciences Conference WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat broadly as a combination therapy across multiple cancer indications, today announced that President and Chief Operating Officer, Read More 05.18.16 Entinostat Data to be Highlighted at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, today announced that clinical data from the National Cancer Institute's Cancer Therapy Evaluation Read More 05.16.16 Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO ENCORE 601 Phase 1b dose escalation has been completed and safety confirmation has commenced at the 5 mg dose Read More 04.26.16 Syndax to Announce First Quarter 2016 Financial Results and Host Conference Call and Live Webcast on May 16, 2016 WALTHAM, Mass., April 26, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its first quarter 2016 financial results on Monday, May 16, 2016, after the closing of the U.S. financial markets. In connection with the earnings release, Syndax's management will host a Read More 04.11.16 Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting WALTHAM, Mass., April 11, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, announced today that entinostat will be the subject of seven investigator presentations, one Read More 03.02.16 Syndax Announces Pricing of Initial Public Offering Syndax Announces Pricing of Initial Public Offering WALTHAM, Mass., March 02, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, announced today that it has priced its initial public Read More 01.20.16 Allan L. Shaw Joins Syndax Pharmaceuticals as Chief Financial Officer Read More 01.04.16 Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer Read More
07.27.16 Syndax Appoints Leading Experts to Scientific Advisory Board (SAB) WALTHAM, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on the development of novel anti-cancer therapies, announced the appointment of seven leading oncology experts to its Scientific Advisory Board (SAB). Read More
07.20.16 Syndax to Announce Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 9, 2016 WALTHAM, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its second quarter 2016 financial results on Tuesday, August 9, 2016, before the opening of the U.S. financial markets. In connection with the earnings release, Syndax's management will host Read More
07.07.16 Syndax Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference WALTHAM, Mass., July 07, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy across multiple cancer indications, today announced that Chief Executive Officer, Briggs Morrison, M.D., Read More
07.06.16 Syndax Expands Pipeline With Exclusive Worldwide License Agreement for UCB's Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program IND-ready immuno-oncology agent has best in class potential Read More
06.14.16 Syndax Pharmaceuticals to Present at the JMP Securities Life Sciences Conference WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat broadly as a combination therapy across multiple cancer indications, today announced that President and Chief Operating Officer, Read More
05.18.16 Entinostat Data to be Highlighted at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, today announced that clinical data from the National Cancer Institute's Cancer Therapy Evaluation Read More
05.16.16 Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO ENCORE 601 Phase 1b dose escalation has been completed and safety confirmation has commenced at the 5 mg dose Read More
04.26.16 Syndax to Announce First Quarter 2016 Financial Results and Host Conference Call and Live Webcast on May 16, 2016 WALTHAM, Mass., April 26, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its first quarter 2016 financial results on Monday, May 16, 2016, after the closing of the U.S. financial markets. In connection with the earnings release, Syndax's management will host a Read More
04.11.16 Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting WALTHAM, Mass., April 11, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, announced today that entinostat will be the subject of seven investigator presentations, one Read More
03.02.16 Syndax Announces Pricing of Initial Public Offering Syndax Announces Pricing of Initial Public Offering WALTHAM, Mass., March 02, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, announced today that it has priced its initial public Read More
01.04.16 Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer Read More